Klotho Neurosciences Inc
KLTO0.388USD
+0.025+7.00%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
27.29MMarket Cap
LossP/E TTM
More Details of Klotho Neurosciences Inc Company
Klotho Neurosciences, Inc. develops essential medicines for the treatment of chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The Company's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The Company's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
Klotho Neurosciences Inc Info
Ticker SymbolKLTO
Company nameKlotho Neurosciences Inc
IPO dateApr 29, 2022
CEOSinkule (Joseph)
Number of employees3
Security typeOrdinary Share
Fiscal year-endApr 29
Address13576 Walnut Street, Suite A
CityOMAHA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code68144
Phone18339316330
Websitehttps://klothoneuro.com/
Ticker SymbolKLTO
IPO dateApr 29, 2022
CEOSinkule (Joseph)
Company Executives of Klotho Neurosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
3.85M
+11.61%
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
736.44K
+26.33%
Mr. Jeffrey (Jeff) LeBlanc
Mr. Jeffrey (Jeff) LeBlanc
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter J. Moriarty
Mr. Peter J. Moriarty
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Riad El-Dada
Mr. Riad El-Dada
Independent Director
Independent Director
--
--
Dr. Shalom Hirschman, M.D.
Dr. Shalom Hirschman, M.D.
Independent Director
Independent Director
--
--
Mr. Jon W. Mcgarity
Mr. Jon W. Mcgarity
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph Sinkule
Dr. Joseph Sinkule
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
3.85M
+11.61%
Dr. Samuel M. Zentman, Ph.D.
Dr. Samuel M. Zentman, Ph.D.
Independent Director
Independent Director
736.44K
+26.33%
Mr. Jeffrey (Jeff) LeBlanc
Mr. Jeffrey (Jeff) LeBlanc
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter J. Moriarty
Mr. Peter J. Moriarty
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Riad El-Dada
Mr. Riad El-Dada
Independent Director
Independent Director
--
--
Dr. Shalom Hirschman, M.D.
Dr. Shalom Hirschman, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sinkule (Joseph)
5.30%
Redwoods Capital LLC
4.61%
Upper Clapton, LLC
3.82%
Austria Capital LLC
2.24%
Centaurus Investment Group Ltd
2.22%
Other
81.81%
Shareholders
Shareholders
Proportion
Sinkule (Joseph)
5.30%
Redwoods Capital LLC
4.61%
Upper Clapton, LLC
3.82%
Austria Capital LLC
2.24%
Centaurus Investment Group Ltd
2.22%
Other
81.81%
Shareholder Types
Shareholders
Proportion
Corporation
12.89%
Individual Investor
8.35%
Investment Advisor
1.38%
Investment Advisor/Hedge Fund
1.03%
Venture Capital
0.11%
Hedge Fund
0.07%
Research Firm
0.03%
Other
76.14%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
57
1.19M
1.69%
-4.24M
2025Q2
58
17.03M
32.31%
-4.86M
2025Q1
69
17.17M
52.84%
-6.48M
2024Q4
79
18.95M
69.99%
-3.66M
2024Q3
79
14.40M
89.14%
-369.26K
2024Q2
77
3.86M
41.12%
-9.95M
2024Q1
73
4.18M
47.51%
-11.23M
2023Q4
73
5.07M
98.15%
-10.93M
2023Q3
69
8.22M
93.39%
-6.83M
2023Q2
67
8.16M
92.70%
-7.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sinkule (Joseph)
3.85M
5.47%
+400.00K
+11.61%
Sep 25, 2025
Redwoods Capital LLC
3.35M
4.76%
--
--
Mar 26, 2025
Upper Clapton, LLC
2.77M
3.94%
--
--
Mar 26, 2025
Austria Capital LLC
1.62M
2.31%
-378.53K
-18.93%
May 14, 2025
Centaurus Investment Group Ltd
1.61M
2.29%
--
--
Mar 26, 2025
Zentman (Samuel M)
736.44K
1.05%
+153.49K
+26.33%
Aug 05, 2025
The Vanguard Group, Inc.
312.50K
0.44%
+312.50K
--
Jun 30, 2025
LeBlanc (Jeff)
511.65K
0.73%
+356.20K
+229.14%
Aug 25, 2025
Hirschman (Shalom Z)
488.72K
0.69%
--
--
Mar 26, 2025
Moriarty (Peter J.)
410.90K
0.58%
--
--
Mar 26, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Klotho Neurosciences Inc?
The top five shareholders of Klotho Neurosciences Inc are:
Sinkule (Joseph) holds 3.85M shares, accounting for 5.47% of the total shares.
Redwoods Capital LLC holds 3.35M shares, accounting for 4.76% of the total shares.
Upper Clapton, LLC holds 2.77M shares, accounting for 3.94% of the total shares.
Austria Capital LLC holds 1.62M shares, accounting for 2.31% of the total shares.
Centaurus Investment Group Ltd holds 1.61M shares, accounting for 2.29% of the total shares.
Sinkule (Joseph) holds 3.85M shares, accounting for 5.47% of the total shares.
Redwoods Capital LLC holds 3.35M shares, accounting for 4.76% of the total shares.
Upper Clapton, LLC holds 2.77M shares, accounting for 3.94% of the total shares.
Austria Capital LLC holds 1.62M shares, accounting for 2.31% of the total shares.
Centaurus Investment Group Ltd holds 1.61M shares, accounting for 2.29% of the total shares.
What are the top three shareholder types of Klotho Neurosciences Inc?
The top three shareholder types of Klotho Neurosciences Inc are:
Sinkule (Joseph)
Redwoods Capital LLC
Upper Clapton, LLC
Sinkule (Joseph)
Redwoods Capital LLC
Upper Clapton, LLC
How many institutions hold shares of Klotho Neurosciences Inc (KLTO)?
As of 2025Q3, 57 institutions hold shares of Klotho Neurosciences Inc, with a combined market value of approximately 1.19M, accounting for 1.69% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -30.62%.
What is the biggest source of revenue for Klotho Neurosciences Inc?
In --, the -- business generated the highest revenue for Klotho Neurosciences Inc, amounting to -- and accounting for --% of total revenue.
